Agranulocytosis remains a very rare adverse event, and the medication continues to be considered safe for the Brazilian population, reaffirmed Fidelis and Hernandez. “However, if a patient experiences symptoms such as sudden fever, chills, sore throat, mouth ulcers, and general weakness after taking dipyrone – especially with prolonged use – we recommend seeking immediate medical evaluation. In addition, it is very important that, in cases of suspected dipyrone-induced agranulocytosis, patients and healthcare professionals report it to Anvisa, even if it is only a suspicion,” they advised.
The study was the result of an international collaboration involving researchers from USP’s School of Pharmaceutical Sciences (FCF), the School of Medical Sciences, and the School of Pharmaceutical Sciences at Unicamp. Also participating were the University of Surabaya (Indonesia), the Uppsala Monitoring Centre (Sweden), and the International Society of Pharmacovigilance (ISoP) in Switzerland.
For more information: emails giovanafsfidelis@gmail.com, with Giovana Fidelis, and carolina.hernandez@usp.br, with professor Carolina Dagli Hernandez
*Intern under the supervision of Moisés Dorado
English version: Nexus Traduções, edited by Denis Pacheco
